CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on ReSonance (ANP1), the Company’s first internally-developed cell transplant program, for the treatment of hearing loss built on its patented and proprietary AlloSCOPE™ manufacturing platform, currently being developed under a research collab
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
